XBIT Stock — XBiotech Inc.: Cash, EV, Pipeline

Share price

$2.19

Market cap

$66.8M

Cash

$109.5M

Enterprise value

-$42.7M

Balance sheet

Cash	$109.5M
Debt	$0.0M
Net cash	$109.5M
Enterprise value	-$42.7M
Basic shares	30.5M shares
Fully diluted shares	35.9M shares
Fully diluted market cap	$78.6M
Cash per share	$3.59

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading XBIT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 26 - Apr 9	Natrunix 400 mg	Phase 2	Rheumatoid Arthritis	—
Oct 13 - Nov 24	vilamakitug	Phase 2	Axial Spondyloarthritis; Ankylosing Spondylitis; r-axSpA	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Natrunix

Stage not disclosed · Active Modality: monoclonal antibody

Target IL-1-alpha

Indications

Pancreatic cancer (oncology) (Stage not disclosed)
Rheumatology (Stage not disclosed)

Status note True Human antibody targeting IL-1-alpha. In 2021 the Company commenced a randomized, double-blinded, placebo-controlled clinical study in pancreatic cancer. A clinical rheumatology program was launched in August 2023 (233 subjects enrolled in a double-blind, placebo-controlled study). Clinical stage not stated in the excerpts.

Hutrukin

Stage not disclosed · Active Modality: monoclonal antibody

Indications

Brain injury following reperfusion (Stage not disclosed)

Status note True Human antibody candidate therapeutic to reduce brain injury occurring after reperfusion; IND filed in 2022. Clinical stage not stated in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Natrunix 400 mg
Lead indication	Rheumatoid Arthritis
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06590090	Phase 2	Not yet recruiting	Sponsor	XBIT	—	Rheumatoid Arthritis	—
NCT06526377	Phase 2	Not yet recruiting	Sponsor	XBIT	—	Axial Spondyloarthritis; Ankylosing Spondylitis; r-axSpA	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for XBiotech, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

XBIT — XBiotech Inc.